GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Halozyme Therapeutics Inc (FRA:RV7) » Definitions » Purchase Of Investment

Halozyme Therapeutics (FRA:RV7) Purchase Of Investment : €-353.9 Mil (TTM As of Mar. 2024)


View and export this data going back to 2004. Start your Free Trial

What is Halozyme Therapeutics Purchase Of Investment?

Halozyme Therapeutics's purchase of investment for the three months ended in Mar. 2024 was €-182.9 Mil. It means Halozyme Therapeutics spent €182.9 Mil on purchasing investments. Halozyme Therapeutics's purchase of investment for the trailing twelve months (TTM) ended in Mar. 2024 was €-353.9 Mil.

Compared with last quarter (€-19.5 Mil in Dec. 2023 ), Halozyme Therapeutics spent more money on purchasing investments in Mar. 2024 (€-182.9 Mil).

Halozyme Therapeutics Purchase Of Investment Historical Data

The historical data trend for Halozyme Therapeutics's Purchase Of Investment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Halozyme Therapeutics Purchase Of Investment Chart

Halozyme Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Purchase Of Investment
Get a 7-Day Free Trial Premium Member Only Premium Member Only -350.78 -185.92 -577.48 -240.92 -268.60

Halozyme Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Purchase Of Investment Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -102.66 - -151.51 -19.53 -182.86

Halozyme Therapeutics Purchase Of Investment Calculation

Purchase of Investments represents cash outflow on the purchase of investments in securities.

Purchase Of Investment for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-353.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Halozyme Therapeutics Purchase Of Investment Related Terms

Thank you for viewing the detailed overview of Halozyme Therapeutics's Purchase Of Investment provided by GuruFocus.com. Please click on the following links to see related term pages.

Halozyme Therapeutics (FRA:RV7) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Halozyme Therapeutics Inc (FRA:RV7) » Definitions » Purchase Of Investment
Comparable Companies
IONS BBIO EXEL CYTK APLS RVMD MDGL BPMC CRSP KRYS OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX
Traded in Other Exchanges
HALO:USA
Address
12390 El Camino Real, San Diego, CA, USA, 92130
Website
https://www.halozyme.com
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme utilizes a strategy that focuses on developing its own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.

Halozyme Therapeutics (FRA:RV7) Headlines

No Headlines